Side effects of chemotherapy for pancreatic cancer

summary

Patients with pancreatic cancer have poor appetite and are thin. Patients with this disease should be treated as soon as possible. Now I will tell you about the side effects of chemotherapy drugs for pancreatic cancer.

Side effects of chemotherapy for pancreatic cancer

Drug 1: gemcitabine (GEM) has unique pharmacological properties and low toxicity. Many basic studies have confirmed that GEM has moderate anti pancreatic cancer effect. Clinical trials show that gem can improve the quality of life and disease-related symptoms of patients with advanced pancreatic cancer, and prolong the survival time.

Drug 2: with the rapid development of molecular biology and genomics, it has been known that the molecular pathogenesis of pancreatic cancer is very complex, and its occurrence, development and metastasis are closely related to a variety of gene mutations and abnormal cellular signal transduction pathways, including ras mutations, cellular signal transduction pathways such as epidermal growth factor receptor (EGFR) pathway, hedgehog signaling pathway and pancreatic cancer The abnormal expression of insulin-like growth factor-1 receptor (IGF-1R) and neovascularization, especially vascular endothelial growth factor pathway. These molecular mechanisms provide multiple potential key targets for the treatment of pancreatic cancer. Therefore, molecular targeted drugs alone or in combination with chemotherapeutic drugs have become a research hotspot in the treatment of pancreatic cancer.

Drug 3: EGFR is a transmembrane glycoprotein family with ligand dependent tyrosine kinase activity. It is overexpressed in a variety of malignant tumors, including pancreatic cancer, and is often closely related to the high invasiveness, rapid progression and poor prognosis of tumors. Co expression of EGFR and its ligand is often observed in pancreatic cancer tissues, which forms autocrine loop and stimulates tumor cell proliferation.

matters needing attention

It has been said that "if we say that hepatocellular carcinoma is the king of cancer, pancreatic cancer is the king of cancer", we can see that it is highly malignant, invasive and lethal. It is difficult to treat advanced patients, and the prognosis is very poor. In 1996, the US FDA first approved gem to replace 5-FU in the treatment of advanced pancreatic cancer. It has been 17 years now. In the meantime, although many scholars have actively explored and tried a variety of cytotoxic drugs in the laboratory and clinic, molecular targeted therapy is also in the ascendant, and drug treatment of advanced pancreatic cancer has made progress, but the overall efficacy and safety are far from satisfactory, mainly because the survival time has not been fundamentally improved, and the "gold standard" status of gem single drug first-line treatment is still difficult to shake In fact, it is a great sorrow for human society and medical circles.